)
Altimmune (ALT) investor relations material
Altimmune AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Opening remarks and agenda
Meeting called to order by the Chairman and held virtually to increase inclusivity and participation.
Formal business outlined in the notice and proxy statement sent to shareholders of record as of March 13, 2026.
Directors, officers, independent auditors, and legal counsel introduced at the start.
Corporate governance
Voting limited to shareholders of record as of March 13, 2026, with procedures for proxy and web portal voting explained.
Quorum established with 88,270,241 shares represented out of 130,105,177 entitled to vote.
Inspector of Election appointed to tabulate results and ensure procedural compliance.
Board and executive committee updates
Nine nominees for director positions presented, all current directors, with no outside nominations received.
Board unanimously recommended voting in favor of all proposals.
- Pemvidutide advances with strong MASH data, regulatory alignment, and promising new indications.ALT
Leerink Global Healthcare Conference 20269 May 2026 - Proxy covers director elections, auditor ratification, compensation, and capital structure changes.ALT
Proxy Filing17 Mar 2026 - Pemvidutide advances with strong MASH data, AI-driven phase III, and expanding late-stage pipeline.ALT
Barclays 28th Annual Global Healthcare Conference12 Mar 2026 - Pemvidutide advances to phase III in MASH, targeting efficacy, tolerability, and market differentiation.ALT
The Citizens Life Sciences Conference 202610 Mar 2026 - Pemvidutide shows robust efficacy and safety in liver disease, advancing to Phase 3 trials.ALT
Corporate presentation10 Mar 2026 - Board seeks approval for director elections, auditor, compensation, and key charter amendments.ALT
Proxy Filing6 Mar 2026 - Phase 3 MASH trial set for 2026 after strong data, FDA support, and robust cash position.ALT
Q4 20255 Mar 2026 - Q2 net loss reached $24.6M as pemvidutide advanced in obesity and MASH trials.ALT
Q2 20242 Feb 2026 - Pemvidutide shows robust efficacy and safety in obesity and MASH, with pivotal data due next year.ALT
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026
Next Altimmune earnings date
Next Altimmune earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)